One possible explanation for these results is that IL-4 treatment results in a change either in the membrane conformation or in the cellular disposition of the FAAH in the prostate cancer cells, so that more is available to the substrate without the need for de novo synthesis, but such an explanation requires further study. The gene discussed is IL4; the disease is prostate cancer.